Search

Your search keyword '"Perol, M."' showing total 498 results
Start Over Author "Perol, M."
498 results on '"Perol, M."'

103. Efficacité du Pembrolizumab en première ligne de prise en charge de cancers du poumon non à petites cellules métastatiques, PDL1 ≥ 50 % avec métastases cérébrales (étude ESCKEYP – GFPC 05–2018)

Author

Descourt, R., Greillier, L., Pérol, M., Ricordel, C., Auliac, J.B., Falchero, L., Gervais, R., Veillon, R., Vieillot, S., Guisier, F., Marcq, M., Justeau, G., Bigay-Game, L., Bernardi, M., Fournel, P., Doubre, H., Pinsolle, J., Amrane, K., Decroisette, C., and Chouaïd, C.

Published
2022
Full Text
View/download PDF

108. MA21.07 Circulating Tumor DNA Analysis Depicts Potential Mechanisms of Resistance to BRAF-Targeted Therapies in BRAF+ Non-Small Cell Lung Cancer

Author

Ortiz-Cuaran, S., primary, Mezquita, L., additional, Swalduz, A., additional, Aldea, M., additional, Mazieres, J., additional, Jovelet, C., additional, Flores, W.R. Chumbi, additional, Lacroix, L., additional, Loriot, Y., additional, Friboulet, L., additional, Westeel, V., additional, Ngocamus, M., additional, Pradines, A., additional, Tissot, C., additional, Duchene, C. Clement, additional, Raynaud, C., additional, Quantin, X., additional, Gervais, R., additional, Brain, E., additional, Monnet, I., additional, Leprieur, E. Giroux, additional, Avrillon, V., additional, Mahier-Aït Oukhatar, C., additional, Hoog-Labouret, N., additional, De Kievit, F., additional, Howarth, K., additional, Guichou, J., additional, Morris, C., additional, Green, E., additional, Perol, M., additional, Besse, B., additional, Blay, J., additional, Saintigny, P., additional, and Planchard, D., additional

Published
2019
Full Text
View/download PDF

109. MA07.05 Immune Checkpoint Inhibitor (ICPi) Re-Challenge: Outcomes Analysis in a French National Cohort of Non-Small-Cell Lung Cancer (NSCLC) Patients

Author

Gobbini, E., primary, Toffart, A.C., additional, Perol, M., additional, Assié, J., additional, Duruisseaux, M., additional, Coupez, D., additional, Gervais, R., additional, Westeel, V., additional, Delaunay, M., additional, Guisier, F., additional, Veillon, R., additional, Gounant, V., additional, Leprieur, E. Giroux, additional, Vanel, F.R., additional, Chaabane, N., additional, Dansin, E., additional, Babey, H., additional, Decroisette, C., additional, Barlesi, F., additional, Girard, N., additional, Fournel, P., additional, Mezquita, L., additional, Oulkhouir, Y., additional, Canellas, A., additional, Duchemann, B., additional, Molinier, O., additional, Moro-Sibilot, D., additional, and Levra, M. Giaj, additional

Published
2019
Full Text
View/download PDF

110. P1.01-116 Early Immune-Related Adverse Events Under PD-1/PD-L1 Inhibitors Predict Better Progression-Free Survival in NSCLC

Author

Boussageon, M., primary, Ortiz-Cuaran, S., additional, Chabaud, S., additional, Pérol, D., additional, Avrillon, V., additional, Mastroianni, B., additional, Fayette, J., additional, Ghiringhelli, F., additional, Neidhardt, E., additional, Swalduz, A., additional, Paulus, V., additional, Kaderbhai, C., additional, Fumet, J., additional, Saintigny, P., additional, and Perol, M., additional

Published
2019
Full Text
View/download PDF

111. Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC: Initial results from the ALK+ cohort

Author

Gadgeel, S.M., primary, Mok, T.S.K., additional, Peters, S., additional, Alexander, J.A.A., additional, Leighl, N.B., additional, Sriuranpong, V., additional, Perol, M., additional, De Castro, G., additional, Nadal, E., additional, De Marinis, F., additional, Han, J.-Y., additional, Yan, M., additional, Riehl, T., additional, Schleifman, E., additional, Paul, S.M., additional, Mocci, S., additional, Shames, D., additional, Mathisen, M.S., additional, and Dziadziuszko, R., additional

Published
2019
Full Text
View/download PDF

114. Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC

Author

Mok, T.S.K., primary, Shaw, A.T., additional, Camidge, R.D., additional, Gadgeel, S.M., additional, Rosell, R., additional, Dziadziuszko, R., additional, Kim, D.-W., additional, Perol, M., additional, Ou, S.-H., additional, Bordogna, W., additional, Smoljanović, V., additional, Hilton, M., additional, and Peters, S., additional

Published
2019
Full Text
View/download PDF

115. Circulating tumour DNA (ctDNA) analysis depicts mechanisms of resistance and tumour response to BRAF inhibitors in BRAF-mutant non-small cell lung cancer (NSCLC)

Author

Ortiz - Cuaran, S., primary, Mezquita, L., additional, Swalduz, A., additional, Aldea, M., additional, Mazieres, J., additional, Jovelet, C., additional, Lacroix, L., additional, Pradines, A., additional, Avrillon, V., additional, MahierAït Oukhatar, C., additional, Hoog-Labouret, N., additional, Howarth, K., additional, Guichou, J.-F., additional, Morris, C., additional, Green, E., additional, Perol, M., additional, Besse, B., additional, Blay, J.-Y., additional, Saintigny, P., additional, and Planchard, D., additional

Published
2019
Full Text
View/download PDF

116. P1.04-30 Pioneer Study: Precision Immuno-Oncology for Advanced Non-Small Cell Lung Cancer Patients with PD1/L1 ICI Resistance

Author

Barlesi, F., primary, Pérol, D., additional, Mazieres, J., additional, Perol, M., additional, Varoqueaux, N., additional, Monville, F., additional, Audigier-Valette, C., additional, Barre, P., additional, Domergue, F., additional, Falchero, L., additional, Foa, C., additional, Frikha, A., additional, Hominal, S., additional, Le Treut, J., additional, Zahi, S., additional, Roumieux, M., additional, Olive, D., additional, and Vivier, E., additional

Published
2019
Full Text
View/download PDF

117. Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: Updated survival and subgroup analysis from the real-world EVIDENS study

Author

Barlesi, F., primary, Dixmier, A., additional, Debieuvre, D., additional, Raspaud, C., additional, Auliac, J.B., additional, Benoit, N., additional, Bombaron, P., additional, Moro-Sibilot, D., additional, Audigier-Valette, C., additional, Asselain, B., additional, Lamoureux, P., additional, Cotté, F.-E., additional, Allan, V., additional, Daumont, M., additional, Ozan, N., additional, Calvet, C., additional, and Perol, M., additional

Published
2019
Full Text
View/download PDF

119. Efficacité et tolérance des inhibiteurs des immuno-checkpoints (anti-PD-1/PD-L1) chez les patients atteint de CBNPC avec mutation EFGR, ALK/ROS : étude IMAD GFPC 03-2016

Author

Bylicki, O., primary, Guisier, F., additional, Monnet, I., additional, Doubre, H., additional, Radj, G., additional, Janicot, H., additional, Perol, M., additional, Fournel, P., additional, Le Treut, J., additional, Lamy, R., additional, Le Caer, H., additional, Auliac, J.B., additional, and Chouaid, C., additional

Published
2019
Full Text
View/download PDF

123. Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer

Author

Smit, E, Garon, E, Reck, M, Cappuzzo, F, Bidoli, P, Cohen, R, Gao, L, O'Brien, L, Lee, P, Zimmermann, A, Ferry, D, Melemed, A, Perol, M, Smit, EF, Garon, EB, Cohen, RB, O'Brien, LM, Ferry, DR, Melemed, AS, Smit, E, Garon, E, Reck, M, Cappuzzo, F, Bidoli, P, Cohen, R, Gao, L, O'Brien, L, Lee, P, Zimmermann, A, Ferry, D, Melemed, A, Perol, M, Smit, EF, Garon, EB, Cohen, RB, O'Brien, LM, Ferry, DR, and Melemed, AS

Abstract

Purpose: Ramucirumab plus docetaxel improved survival in REVEL, a randomized phase 3 trial for patients with Stage IV non-small cell lung cancer after standard platinum-based chemotherapy. This exploratory analysis evaluated the exposure–response relationship of ramucirumab from REVEL. Methods: Patients received ramucirumab (10 mg/kg) or placebo plus docetaxel (75 mg/m2) every 3 weeks. Pharmacokinetic samples were collected. A population pharmacokinetic analysis predicted ramucirumab minimum concentration after first-dose administration (Cmin,1) and average concentration at steady state (Cave,ss). Predicted Cmin,1 and Cave,ss were used to evaluate the relationship between ramucirumab exposure and efficacy and safety, respectively. Exposure–efficacy was assessed by Kaplan–Meier and Cox regression analyses; exposure–safety was assessed by ordered categorical analyses. Results: Analyses included 376 patients treated with ramucirumab plus docetaxel and 366 patients treated with placebo plus docetaxel (364 for safety population). After adjusting for corresponding prognostic factors, the association between overall survival (OS) and Cmin,1 was statistically significant (p = 0.0110), although progression-free survival (PFS) showed a marginal association (p = 0.0515). At high ramucirumab exposures (Cmin,1), greater improvements (smaller hazard ratios) were seen for OS and PFS when stratified by Cmin,1 exposure quartiles. A statistically significant correlation was observed between ramucirumab Cave,ss and grade ≥ 3 febrile neutropenia and hypertension. Conclusions: An association was observed between ramucirumab exposure and efficacy. Higher ramucirumab exposure was associated with improved clinical outcomes and increased toxicity in this analysis. Two exposure–response prospective randomized trials are being conducted to address causation (NCT02443883 and NCT02514551), with encouraging preliminary results (Ajani et al. in Ann Oncol 28:abstr 698P, 2017).

Published
2018

129. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1

Author

Robinet, G., Thomas, P., Breton, J.L., Léna, H., Gouva, S., Dabouis, G., Bennouna, J., Souquet, P.J., Balmes, P., Thiberville, L., Fournel, P., Quoix, E., Riou, R., Rebattu, P., Pérol, M., Paillotin, D., and Mornex, F.

Published
2001
Full Text
View/download PDF

132. Programme épidémio-stratégie médicoéconomique : une base nationale de données de vie réelle pour mieux comprendre la prise en charge du cancer bronchopulmonaire en France

Author

Pérol, M., Carton, M., Debieuvre, D., Quantin, X., Girard, N., Audigier-Vallette, C., Lena, H., Filleron, T., Schott, R., Gervais, R., Hiret, S., Otto, J., Dansin, E., Dubray Longeras, P., Kaderbhai, C., Madroszyk, A., Clément-Duchêne, C., Pichon, E., Planchard, D., Lemoine, A., Thureau, S., Baranzelli, A., Cousin, S., Schneider, S., Bizieux, A., Le Treut, J., Hominal, S., Dayen, C., Simon, G., Robain, M., Couch, D., and Chouaid, C.

Published
2021
Full Text
View/download PDF

133. Prise en charge des patients atteints d’un cancer bronchopulmonaire à petites cellules de stade IV – Analyse de la base nationale de données de vie réelle du programme Épidémio-Stratégie Médico-Économique (ESME)

Author

Audigier-Valette, C., Filleron, T., Debieuvre, D., Kaderbhai, C., Lena, H., Cousin, S., Gervais, R., Schott, R., Otto, J., Dubray Longeras, P., Girard, N., Pérol, M., Chouaid, C., Pichon, E., Hominal, S., Madroszyk, A., Lemoine, A., Hiret, S., Schneider, S., Dansin, E., Planchard, D., Baranzelli, A., Bizieux, A., Clément-Duchêne, C., Le Treut, J., Dayen, C., Couch, D., Thureau, S., Robain, M., Simon, G., and Quantin, X.

Published
2021
Full Text
View/download PDF

134. Analyse FONctionnelle des mutations identifiées au voisinage de l’exon 14 du gène MET et efficacité du crizotinib chez des patients atteints d’un carcinome broncho-pulmonaire non à petites cellules de stade avancé (CBNPC) : étude GFPC-AFonMET

Author

Babey, H., Jamme, P., Gervais, R., Assié, J.B., Veillon, R., Doubre, H., Pérol, M., Guisier, F., Huchot, E., Decroisette, C., Falchero, L., Chiappa, A.M., André, M., Cortot, A., Chouaid, C., Le Gac, G., and Descourt, R.

Published
2021
Full Text
View/download PDF

135. Traitements de première ligne et prise en charge du cancer broncho-pulmonaire non à petites cellules avancé ou métastatique avec une mutation EGFR–Analyse de la base nationale de données de vie réelle du programme Épidémio-stratégie médico-économique

Author

Girard, N., Filleron, T., Pérol, M., Chouaid, C., Debieuvre, D., Quantin, X., Dayen, C., Lena, H., Schott, R., Gervais, R., Schneider, S., Otto, J., Dansin, E., Dubray Longeras, P., Kaderbhai, C., Madroszyk, A., Clément-Duchêne, C., Pichon, E., Planchard, D., Lemoine, A., Bizieux, A., Baranzelli, A., Cousin, S., Couch, D., Hominal, S., Thureau, S., Le Treut, J., Robain, M., Hiret, S., Simon, G., and Audigier-Vallette, C.

Published
2021
Full Text
View/download PDF

136. Biomarker-driven access to crizotinib in ALK, MET or ROS1 positive (+) malignancies in adults and children: The French national AcSé program

Author

Vassal, G., primary, Cozic, N., additional, Houot, R., additional, Brugières, L., additional, Aparicio, T., additional, Blay, J.-Y., additional, Perol, M., additional, Brice, P., additional, Meriaux, E., additional, Geoerger, B., additional, El Bejjani, M.R., additional, Moalla, S., additional, Bièche, I., additional, Lantuejoul, S., additional, Mahier Ait Oukhatar, C., additional, Hoog Labouret, N., additional, and Moro-Sibilot, D., additional

Published
2018
Full Text
View/download PDF

137. Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma: Data from a French multicentric cohort

Author

Domblides, C., primary, Monnet, I., additional, Mazieres, J., additional, Barlesi, F., additional, Gounant, V., additional, Baldacci, S., additional, Mennecier, B., additional, Toffart, A.C., additional, Audigier Valette, C., additional, Doucet, L., additional, Giroux-Leprieur, E., additional, Guisier, F., additional, Molinier, O., additional, Perol, M., additional, Pichon, E., additional, Robinet, G., additional, Templement Grangerat, D., additional, Ruppert, A.-M., additional, and Wislez, M., additional

Published
2018
Full Text
View/download PDF

138. EVIDENS: An observational study of nivolumab-treated patients in advanced non-small cell lung cancer (NSCLC) in a real-world setting: Initial results on 1394 patients

Author

Dixmier, A., primary, Debieuvre, D., additional, Raspaud, C., additional, Auliac, J.B., additional, Benoit, N., additional, Bombaron, P., additional, Asselain, B., additional, Dumont, A., additional, Lamoureux, P., additional, Goyard, N., additional, Moro-Sibilot, D., additional, Perol, M., additional, Barlesi, F., additional, and Audigier Valette, C., additional

Published
2018
Full Text
View/download PDF

139. Clinical outcomes in patients with advanced NSCLC treated with targeted therapies, with actionable mutations identified by InVisionFirst ctDNA assay

Author

Remon, J., primary, Mezquita, L., additional, Ortiz-Cuaran, S., additional, Jovelet, C., additional, Lacroix, L., additional, Morris, C., additional, Green, E., additional, Saintigny, P., additional, Besse, B., additional, Swalduz, A., additional, Howarth, K., additional, Rouleau, E., additional, De Kievit, F., additional, Baker-Neblett, K., additional, Roitt, S., additional, Plagnol, V., additional, Perol, M., additional, and Planchard, D., additional

Published
2018
Full Text
View/download PDF

141. Activité de l’osimertinib dans les méningites carcinomateuses des cancers non à petites cellules (CPNPC) avec mutation activatrice de l’EGFR ayant déjà bénéficié d’un traitement par inhibiteur tyrosine-kinase (TKI) de l’EGFR

Author

Saboundji, K., primary, Auliac, J.B., additional, Perol, M., additional, François, G., additional, Janicot, H., additional, Marcq, M., additional, Dubos Arvis, C., additional, Renault, P.A., additional, Guisier, F., additional, Odier, L., additional, Gervais, R., additional, and Chouaid, C., additional

Published
2018
Full Text
View/download PDF

143. Étude de phase III évaluant dans le cancer bronchique non à petites cellules de stade IV et d’histologie non épidermoïde ; deux stratégies de maintenance, l’une par pémétrexed en maintenance de continuation, l’autre en fonction de la réponse à la chimiothérapie d’induction : essai IFCT-GFPC 11-01

Author

Souquet, P.J., primary, Audigier-Valette, C., additional, Molinier, O., additional, Cortot, A., additional, Margery, J., additional, Hominal, S., additional, Tredaniel, J., additional, Jeanfaivre, T., additional, Kiakouama-Maleka, L., additional, Locher, C., additional, Herman, D., additional, Marcq, M., additional, Daniel, C., additional, Merle, P., additional, Vergnenegre, A., additional, Dixmier, A., additional, Amour, E., additional, Langlais, A., additional, and Perol, M., additional

Published
2018
Full Text
View/download PDF

144. Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer

Author

Reck, M, Paz-Ares, L, Bidoli, P, Cappuzzo, F, Dakhil, S, Moro-Sibilot, D, Borghaei, H, Johnson, M, Jotte, R, Pennell, N, Shepherd, F, Tsao, A, Thomas, M, Carter, G, Chan-Diehl, F, Alexandris, E, Lee, P, Zimmermann, A, Sashegyi, A, Perol, M, Pennell, NA, Shepherd, FA, Carter, GC, Reck, M, Paz-Ares, L, Bidoli, P, Cappuzzo, F, Dakhil, S, Moro-Sibilot, D, Borghaei, H, Johnson, M, Jotte, R, Pennell, N, Shepherd, F, Tsao, A, Thomas, M, Carter, G, Chan-Diehl, F, Alexandris, E, Lee, P, Zimmermann, A, Sashegyi, A, Perol, M, Pennell, NA, Shepherd, FA, and Carter, GC

Abstract

Objectives The REVEL study demonstrated improved efficacy for patients with advanced non-small cell lung cancer treated with ramucirumab plus docetaxel, independent of histology. This exploratory analysis characterized the treatment effect in REVEL patients who were refractory to prior first-line treatment. Materials and methods Refractory patients had a best response of progressive disease to first-line treatment. Endpoints included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), quality of life (QoL), and safety. Kaplan-Meier and Cox proportional hazards regression were performed for OS and PFS, and Cochran-Mantel-Haenszel test was used for response. QoL was assessed with the Lung Cancer Symptom Scale. Sensitivity analyses were performed on subgroups of the intent-to-treat population with limited time on first-line therapy. Results Of 1253 randomized patients in REVEL, 360 (29%) were refractory to first-line treatment. Baseline characteristics were largely balanced between treatment arms. In the control arm, median OS for refractory patients was 6.3 versus 10.3 months for patients not meeting this criterion, demonstrating the poor prognosis of refractory patients. Median OS (8.3 vs. 6.3 months; HR, 0.86; 95% CI, 0.68–1.08), median PFS (4.0 vs. 2.5 months; HR, 0.71; 95% CI, 0.57–0.88), and ORR (22.5% vs. 12.6%) were improved in refractory patients treated with ramucirumab compared to placebo, without new safety concerns or further deteriorating patient QoL. Conclusions The effect of ramucirumab in refractory patients is similar to that in the intent-to-treat population. The benefit/risk profile for refractory patients suggests that ramucirumab plus docetaxel is an appropriate treatment option even in this difficult-to-treat population.

Published
2017

145. 1242P Characteristics of the first 615 patients enrolled in Pacific R: A study of the first real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

Author

Girard, N., Fietkau, R., Garassino, M., Garrido, P., Field, J.K., Peters, S., Smit, H.J.M., Pérol, M., Merle, P., Sibille, A., Markman, B., Bouchaab, H., Moskovitz, M., Schumann, C., Gregorc, V., Klein, A.B., Diaz Perez, I., Sawyer, W., Licour, M., and Christoph, D.

Published
2020
Full Text
View/download PDF

146. LBA53 Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients (pts) treated with PD1/L1 immune checkpoint inhibitors (ICIs): A first analysis of the PIONeeR study

Author

Barlesi, F., Greillier, L., Monville, F., Foa, C., J. le Treut, Audigier-Valette, C., Vély, F., Garcia, S., Sabatier, F., Ciccolini, J., Fabre, M., Le Ray, M., Resseguier, N., Outters, P., Roumieux, M., Mazieres, J., Pérol, M., Vivier, E., Auquier, P., and Fieschi, J.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results